South Korean biopharma company Celltrion has reportedly signed agreements with nine European countries to provide Regkirona (regdanvimab), a monoclonal antibody therapy for COVID-19. Given the increasing COVID-19 cases and exhaustion pace of the initial supply, Celltrion Healthcare expressed they expect the countries to order additional Regkirona vials this year itself. However, investors do not seem thrilled despite the latest developments in Regkirona supply and licensing. The company received an unenthusiastic response from the stock market, with the Celltrion stock closing at 207,000 won (USD 175.1) on Tuesday, similar to that before the European approval. Celltrion Pharm and Celltrion Healthcare shares also remained sluggish on the same day, ending at 120,000 won (USD 101.86) and 81,000 won (USD 68.76), respectively.

Source: Economic Times December 01, 2021 19:09 UTC